Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Promising Innovative Medicine

NAVIGATING 2022: THE FIVE CRITICAL SHIFTS PHARMA NEEDS TO EMBRACE

With a stormy outlook predicted for health and care, Wilmington Healthcare’s Oli Hudson looks at the five critical shifts that pharma should focus on as it navigates its way through...

Wilmington Healthcare

- PMLiVE

MHRA approves second COVID-19 antibody treatment

Preclinical data for GSK and Vir’s Xevudy suggests it retains activity against Omicron and all other variants of concern

- PMLiVE

UK’s MHRA approves first oral antiviral against COVID-19

Merck's Lagevrio has been approved for people with mild to moderate COVID-19 and at least one risk factor for developing severe illness

CHANGING FACES: UNDERSTANDING THE KEY CUSTOMER CONTACT POINTS WITHIN THE ICS LANDSCAPE

As well as creating new structures, the reforms underway within the NHS will see a considerable movement of people and power across the new Integrated Care Systems. Wilmington Healthcare’s Victoria...

Wilmington Healthcare

- PMLiVE

Future of MHRA uncertain amid Brexit-fuelled shake up

Trade unions and regulatory experts warn that budget and staff cuts may lead to drug approval delays or the UK regulator simply rubber-stamping EMA decisions

regeneron headquarters

UK approves Regeneron’s COVID-19 antibody cocktail

Ronapreve is the first monoclonal antibody therapy against COVID-19 approved in Europe

- PMLiVE

NICE approval for Lilly’s Verzenios is “fantastic news for thousands of women”

NICE declares Lilly’s breast cancer drug to be cost-effective, allowing routine use on the NHS

- PMLiVE

UK’s CMA fines drugmakers £260m for overcharging NHS for steroid med

Three of the ten companies named in CMA’s statement said they disagreed with the decision and would be appealing against the fines

- PMLiVE

UK announces new ten-year Life Sciences Vision to support life sciences sector

UK government has launched a £200m life sciences investment programme to support innovative life sciences companies

- PMLiVE

MHRA outlines two-year delivery plan with ‘patient first’ focus

New delivery plan also outlines strategy for UK regulatory body following Brexit

- PMLiVE

UK Supreme Court rules in favour of Servier in NHS patent lawsuit

The NHS alleged that the French pharma company tried to block sales of generics versions of its drug Coversyl

- PMLiVE

MHRA grants bluebird bio’s LentiGlobin gene therapy an ‘innovation passport’

The Innovative Licensing and Access Pathway scheme aims to help speed approval of innovative treatments

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links